Direct cost for metastatic breast cancer patients increases dramatically when their treatment differs from recommendations in the NCCN Clinical Practice Guidelines in Oncology.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
